Target intelligence / Profile preview

Immunoglobulin kappa variable 2-30 (IGKV2-30)

Target
IGKV2-30
Molecular classification
Immunoglobulin variable region gene, Antibody light chain variable domain, Protein coding gene
01

Overview

Immunoglobulin kappa variable 2-30 is a variable region gene segment encoding the variable domain of the kappa light chain of immunoglobulins (antibodies)[1]. The encoded region participates in antigen recognition by contributing to the antigen binding site of the antibody, pairing with heavy chain variable regions to confer specificity and diversity. This gene segment is expressed in B lymphocytes, where, after V-J rearrangement and possible somatic hypermutation, it helps generate the diverse antibody repertoire essential for humoral immunity. IGKV2-30 is part of the immunoglobulin kappa locus on chromosome 2 and is classified as a variable region gene (not a receptor, enzyme, or druggable therapeutic target). It is not itself a direct therapeutic target, drug target, or disease driver, but it contributes genetically and structurally to the antigen-binding properties of antibodies[1][3][4].

Other names
IGKV2-30IGKV230Ig kappa chain V-II region RPMI 6410A17
02

Biological functions

Antigen bindingImmune responseHumoral immunity (B cell receptor/antibody formation)
03

Disease associations

Other (Not a direct disease driver but can contribute to antibody-mediated immune response in infection, inflammation, autoimmunity, or cancer when paired with specific heavy chains)

Beyond the preview

Go deeper on Immunoglobulin kappa variable 2-30 (IGKV2-30).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin kappa variable 2-30 (IGKV2-30).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call